These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38176896)

  • 1. Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients.
    Uzawa A; Mori M; Masuda H; Uchida T; Muto M; Ohtani R; Aoyama S; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):626-629. PubMed ID: 38176896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability.
    Cho EB; Min JH; Cho HJ; Seok JM; Lee HL; Shin HY; Lee KH; Kim BJ
    J Neurol Sci; 2016 Nov; 370():214-218. PubMed ID: 27772762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
    Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
    Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum.
    Park SY; Kwon YN; Kim S; Kim SH; Kim JK; Kim JS; Nam TS; Min YG; Park KS; Park JS; Seok JM; Sung JJ; Sohn E; Shin KJ; Shin JH; Shin HY; Oh SI; Oh J; Yoon BA; Lee S; Lee JM; Lee HL; Choi K; Huh SY; Jang MJ; Min JH; Kim BJ; Kim SM
    J Neurol Neurosurg Psychiatry; 2023 Oct; 94(10):800-805. PubMed ID: 37268404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue.
    Tackley G; Kong Y; Minne R; Messina S; Winkler A; Cavey A; Everett R; DeLuca GC; Weir A; Craner M; Tracey I; Palace J; Stagg CJ; Emir U
    Neuroimage; 2021 Sep; 238():118225. PubMed ID: 34062267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
    J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
    Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
    Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
    Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD.
    Carnero Contentti E; Delgado-García G; Criniti J; López PA; Pettinicchi JP; Cristiano E; Miguez J; Correa-Díaz EP; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Tkachuk V; Caride A; Rojas JI
    Front Immunol; 2021; 12():628024. PubMed ID: 33717149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.